Is extending life by weeks worth the toll some cancer drugs take? Doctors push for 'commonsense oncology'
Tom Somerville's decision stop medical treatment for his end-stage cancer was a personal one.
Somerville, 62, was diag‐ nosed with colon cancer in 2021 that later spread to his liver. He had six months of chemotherapy to slow down the cancer, which he said al‐ so left him exhausted with nausea.
The Kingston, Ont., resi‐ dent decided to take a break from treatment to enjoy a trip with his wife to Victoria.
"Things that you cherish change, right?" Somerville said. "I used to love being out in the bush, but now it is just nice to have a sunny day, sit with my family [and] have visitors."
Somerville said he came to terms with his prognosis and decided to enjoy the rest of the life he has left, extend‐ ing the chemo break to a full stop. He said he was relieved to not "feel crappy" from the treatment anymore.
Dr. Christopher Booth, Somerville's medical oncolo‐ gist at Kingston General Hos‐ pital, supports him in his de‐ cision.
Booth is also part of a group of cancer doctors in Canada and the U.S. who say medications with marginal benefits are overused for pa‐ tients in the end stage of the disease. The oncologists have started a campaign through their website, journal articles and podcasts encouraging honest conversations about use of the drugs with cancer patients, their families and experts.
The goal of what they call "common-sense oncology" is to prioritize treatments that meaningfully improve sur‐ vival and quality of life. They aim to address what they see as problems in the field, such as a lack of critical thinking in oncology training, falling
standards for drug approvals and avoidance of end-of-life discussions.
Balancing hope and real‐ ity
Booth said while there have been incredible ad‐ vances in cancer treatments in his 20 years of practice, there's also an unfortunate reality: cancer can't always be cured. He strives to con‐ vey it in a compassionate and clear way.
"Balancing … providing in‐ formation but also providing hope, that's the art of cancer care," Booth said. "Balancing hope and reality, balancing treatment and quality of life and side-effects, that's the tough part of this job."
Booth said he thinks everyone would agree that a treatment that helps a pa‐ tient live for extra months or years is very helpful. But when a treatment buys weeks with a lot of side-effec‐ ts, then patient perspectives may differ.
In part that's because the cancer drugs that can shrink tumours also come with sideeffects, including fatigue, vomiting and hair loss.
Dr. Bishal Gyawali, a med‐ ical oncologist and associate professor at Queen's Univer‐ sity in Kingston, was moti‐ vated to press for changes when he noticed increased spending on treatments that don't make much difference in patients' lives while at the same time agencies didn't put resources to what's al‐ ready been proven to work.
Gyawali previously treated people with cancer in Nepal, Japan, and the U.S. and saw the same trends there.
When attending oncology conferences, Gyawali said presenters would celebrate a two-week improvement in survival from a new treat‐ ment. Then, behind closed doors, other delegates would talk about the risks and costs of the drug.
"People are saying is this really meaningful?"
Gyawali aims to normalize asking such questions.
Quality of life and quan‐ tity
Rachel Koven's husband, Ken Koven, was diagnosed in his late 40s with adenocarci‐ noma, which starts in gland cells of the esophagus tube. His cancer was found where the esophagus meets the stomach.
The father and avid run‐ ner treated having cancer like a battle, his wife said. He had nine months of palliative chemotherapy that's given to relieve the symptoms of can‐ cer and improve quality of life, but not meant to cure the malignancy.
The cancer spread. He then underwent radiation to the brain in Kingston, Ont. In 2016, about 16 months after the diagnosis, he died at age 49.
"For my husband, his hope was anchored in treat‐ ment," Koven said. "However well-rounded the discussions we had, he would have al‐ ways chosen treatment, and I can't begrudge him for that because that is where he be‐ lieved his strength was."
Now, Koven feels families should ask more questions of doctors, such as:
How much time does this treatment offer? What are the real costs and benefits of the treatment?
Koven said not having treatment is sometimes seen as throwing in the towel, but that can be misleading.
"Not having treatment is‐ n't giving up," Koven said. "Sometimes by having treat‐ ment you are giving up. You are giving up time with your family. You are giving up a quality of life necessarily for something you are not trad‐ ing off any extra days."
Koven wrote an essay in 2018 on her experience as her husband's caregiver in the Canadian Medical Associ‐ ation Journal. At the time, she was motivated "to contribute to the best possible life in the face of death."
Now Koven advocates for the oncology field to "recali‐ brate" toward an emphasis on what brings the person joy rather than only focusing on treating their cancer. Find‐ ing novel treatments that will really benefit patients is also important to her.
Seek meaningful an‐ swers
Dr. Elizabeth Eisenhauer ran more than 170 cancer drug trials in Canada, the U.S. and Europe. Now retired, Eisenhauer won the 2021 Canada Gairdner Wightman Award for investigating new cancer drugs and delivery ap‐ proaches, including for Taxol, an anti-cancer treatment.
"It's a good thing we are having so much interest in finding novel therapeutics for cancer," Eisenhauer said. "But my goodness, let's find the answers that matter to patients, too."
Eisenhauer recalled how in the 1980s, scientists set an arbitrary number as a stan‐ dard, worldwide indicator of safe tumour shrinkage for early clinical trial research.
WATCH | Promise and limitations of AI to detect cancer:
After that, measuring whether a tumour grew by 20 per cent on a CT scan, the de‐ finition of progression, be‐ came an endpoint, or goal, for pharmaceutical com‐ panies running randomized trials, Eisenhauer said. Ran‐ domized trials are meant to guide whether a drug should be used as a standard of care by physicians.
"You have an answer sooner [using tumour shrink‐ age], but is it an answer that is meaningful?" she said.
Eisenhauer would like to see cancer clinical trials in‐ clude more criteria.
"I think common-sense oncology from my perspec‐ tive as a trialist needs to come from the perspective of trying to be sure that the tri‐ als that we design at least can capture the information that will be of importance to those discussions with the patient sitting in front of you."
Eisenhauer said there aren't a huge number of game changers in oncology every year, but many are available in Canada. She said costs to patients in terms of side-effects and time coming to the clinic also need to be considered.
Despite that, other Cana‐ dian researchers looking last year at use of treatments like chemotherapy or major surg‐ ery among more than 151,000 people who died found that a treatment was commonly given - in 41 per cent of cases - in the last 30 days of life but was potential‐ ly inappropriate.
So far, Gywali said the common-sense oncology movement is gaining mo‐ mentum worldwide and he's received positive feedback from regulators, physicians, patients and payers.
WATCH | Why some can‐ cer patients choose to pause treatment:
Tom and Katherine Somerville now take time every day to enjoy moments together, like walking down to the pond near their farm‐ house, going for a drive on a sunny day or listening to old tunes.
For them, quality of life in‐ cludes loving glances.
"You appreciate that mo‐ ment and you want to take it all in and those are the sim‐ ple things that you realize are not so simple," Katherine said. "They're the important things."